imatinib teva pharma 400 milligram film coated tablet
teva pharma b.v. - imatinib mesilate - film coated tablet - 400 milligram - protein kinase inhibitors
imatinib teva pharma 100 milligram film coated tablet
teva pharma b.v. - imatinib mesilate - film coated tablet - 100 milligram - protein kinase inhibitors
lercanidipine teva pharma 10 milligram film coated tablet
teva pharma b.v. - lercanidipine hydrochloride - film coated tablet - 10 milligram - dihydropyridine derivatives
lercanidipine teva pharma 20 milligram film coated tablet
teva pharma b.v. - lercanidipine hydrochloride - film coated tablet - 20 milligram - dihydropyridine derivatives
imatinib teva pharma 100 mg film-coated tablets
teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - imatinib - film-coated tablet - imatinib 100 mg - antineoplastic agents
imatinib teva pharma 400 mg film-coated tablets
teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - imatinib - film-coated tablet - imatinib 400 mg - antineoplastic agents
carbamazepine essential pharma
essential pharma ltd - carbamazepine - suppositories - 125 milligram - carbamazepine
carbamazepine essential pharma
essential pharma ltd - carbamazepine - suppositories - 250 milligram - carbamazepine
clopidogrel teva pharma b.v.
teva pharma b.v. - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome: non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.
ketorolac tromethamine tablet, film coated
denton pharma, inc. dba northwind pharmaceuticals - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine 10 mg - carefully consider the potential benefits and risks of ketorolac tromethamine tablets usp and other treatment options before deciding to use ketorolac tromethamine tablets usp. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. ketorolac tromethamine tablets usp are indicated for the short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with iv or im dosing of ketorolac tromethamine and ketorolac tromethamine tablets usp are to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine tablets usp and ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings , precautions , dosage and administrati